AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSE-ESCALATION AND EXTENSION, PHASE IA/IB STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS

Published: 22-01-2020
Last updated: 25-09-2024

This study has been transitioned to CTIS with ID 2023-503749-76-00 check the CTIS register for the current data. This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety,pharmacokinetics, immunogenicity, and pharmacodynamics of...

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Other condition
Study type	Interventional

Summary

ID

NL-OMON55111

Source
ToetsingOnline

Brief title
BP41628

Condition

- Other condition

Synonym
metastatic solid tumors

Health condition

metastatic solid tumors

Research involving
Human

Sponsors and support

Primary sponsor: Roche Nederland B.V.
Source(s) of monetary or material Support: F Hoffman La Roche inc

Intervention

Keyword: ATEZOLIZUMAB, DOSE ESCALATION, Phase 1A/1B, SOLID TUMORS

Outcome measures

Primary outcome

Primary objectives:

- To evaluate the safety and tolerability of RO7284755 alone (Part 1) or in

combination with atezolizumab (Part 2)

Endpoint: Incidence, nature, and severity of adverse events (AEs) graded

according to the National Cancer Institute (NCI) Common Terminology Criteria

for Adverse Events (CTCAE)

- To determine the maximum-tolerated dose (MTD) and/or the recommended dose for

extension (RDE) of RO7284755 (Part 1 and Part 2) Endpoint: Nature and frequency

of dose-limiting toxicities (DLTs)

- To evaluate the anti-tumor activity of study treatment (Part 3)

Endpoint: Objective response rate (ORR) according to RECIST v1.1

Secondary outcome

To evaluate the anti-tumor activity of study treatment (Part 1 and Part 2)

To evaluate the safety and tolerability of the study treatment (Part 3)

The precise secondary and Exploratory objectives and endpoints are stated in

section3, table 9 of the protocol.

Study description

Background summary

RO7284755, a PD-1 targeted IL-2 variant immunocytokine, is being developed for the treatment of patients with advanced and/or metastatic solid tumors.
A detailed description of the background of disease, current therapies, unmet medical needs as well as a description of chemistry, pharmacology, efficacy, and safety of RO7284755 is provided in the Investigator*s Brochure.

Section 2 of the protocol extensively describes the background and rationale of the study.

Study objective

This study has been transitioned to CTIS with ID 2023-503749-76-00 check the CTIS register for the current data.

This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of RO7284755 (alone or in combination with atezolizumab) and to evaluate its anti-tumor activity.

Study design

This is an EIH, open-label, multicenter, randomized, Phase Ia/Ib, adaptive, multiple ascending dose study of RO7284755 as single agent or in combination

with atezolizumab.
The study will enroll adult participants with solid tumors considered responsive to checkpoint inhibition blockade, as described in Section 5.
The study consists of 3 parts: dose-escalation of RO7284755 as a single agent (Part 1), dose-escalation of RO7284755 in combination with atezolizumab (Part 2), and extension of RO7284755 as a single agent and/or in combination with atezolizumab (Part 3).
The treatment groups in the different parts of the study design are as follows:

Part 1: Dose-Escalation of RO7284755 as a Single Agent
Part 2: Dose-Escalation of RO7284755 in Combination with Atezolizumab
Part 3: Extension of RO7284755 as a Single Agent and/or in Combination with Atezolizumab Prior to start

Intervention

For the purpose of the study, RO7284755 and atezolizumab are considered investigational medicinal products (IMPs).

An overview of all treatments is given in Tables 1-4 and 7.
In Figures 1-3 of the protocol a schematic overview is given of the study design.

Study burden and risks

RO7284755 is not given in humans before.
Risks and possible side affects are described in section 6 and in appendix D of the ICF

Contacts

Public
Roche Nederland B.V.

Beneluxlaan 2a
Woerden 3446 GR
NL
Scientific
Roche Nederland B.V.

Beneluxlaan 2a
Woerden 3446 GR
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- Age >=18 years
- Locally advanced/unresectable or metastatic disease
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group Performance Status 0 to 1
- Life expectancy of >= 12 weeks
- Consent to provide an archival tumor tissue sample
- Adequate cardiovascular, hematological, coagulative, hepatic and renal function
- Female Participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, woman of childbearing potential (WOCBP) must agree to remain abstinent or use of two, highly effective contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 1 month after last dose of RO7284755 or at least 5 months after the last dose of atezolizumab whichever is longer

Exclusion criteria

- Rapid disease progression or suspected hyperprogression or threat to vital organs or critical anatomical sites requiring urgent alternative medical intervention
- Known active central nervous system (CNS) metastases
- History of treated asymptomatic CNS metastases
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >= 2 weeks before Cycle1 Day 1 (C1D1)

- Active or history of carcinomatous meningitis/leptomeningeal disease
- Uncontrolled tumor-related pain or symptomatic hypercalcemia
- Concurrent second malignancy
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
- Episode of significant cardiovascular/cerebrovascular acute disease within 28 days before study treatment administration
- Active or uncontrolled infections
- Known HIV infection
- Hepatitis B virus (HBV) or hepatitis C virus infection
- Adverse events related to any prior radiotherapy, chemotherapy, targeted therapy, CPI therapy or surgical procedure must have resolved to Grade <=1, except alopecia Grade 2 peripheral neuropathy, and hypothyroidism and/or hypopituitarism on a stable dosage of hormone replacement therapy
- Participants with bilateral pleural effusion
- Major surgery or significant traumatic injury < 28 days before study treatment administration or anticipation of the need for major surgery during study treatment
- Known allergy or hypersensitivity to any component of the formulations of the IMPs to be administered, including but not limited to hypersensitivity to Chinese hamster ovary cell products or other recombinant or humanized antibodies
- History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins

Study design

Design

Study type: Interventional

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	02-07-2020
Enrollment:	34
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Atezolizumab - ANTI-PD-L1
Generic name:	Tecentric
Registration:	Yes - NL outside intended use
Product type:	Medicine
Brand name:	PD-1 IL-2v
Generic name:	PD-1 IL-2v

Ethics review

Approved WMO Date:	22-01-2020
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	23-03-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	06-04-2020
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	11-06-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	18-06-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Approved WMO Date:	30-09-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	27-10-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	16-11-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	28-12-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	30-12-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	10-03-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	26-03-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	17-09-2021
Application type:	Amendment

Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	25-10-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	30-11-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	14-12-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	07-02-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	27-05-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	30-08-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	22-10-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO	

Date:	10-11-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	02-12-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	03-01-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	14-06-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	14-08-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EU-CTR	CTIS2023-503749-76-00
EudraCT	EUCTR2019-004022-25-NL
CCMO	NL72306.056.20